Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

Exclusion criteria

• ✕. Participants with a history of congestive heart failure or uncontrolled diabetes.
• ✕. Participants with serious hepatic, respiratory, hematologic or immunologic illnesses, an unstable cardiovascular disease, or any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or Erenumab or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the participant inappropriate for entry into this trial.
• ✕. Participants with high blood pressure, uncontrolled high blood pressure, malignant disease, chronic constipation, any malabsorption disorders such as IBSc or any other severe acute or chronic medical or psychiatric condition (major depression, schizophrenia, dementia) or laboratory finding that may increase the risk associated with trial participation with Erenumab, that in the judgement of the investigators would interfere with study assessments and/or would make the participant inappropriate for entry into this trial.
• ✕. Participants with active malignancy of any type or a history a malignancy (with exception of participants with malignancy surgically removed with no evidence of recurrence within 5 years before enrollment.
• ✕. Participants with evidence or a history of drug or alcohol abuse within the past 12 months or has been diagnosed with a substance abuse disorder.
• ✕. Participants with dental pain (determined pain of odontogenic/periodontal origin).
• ✕. Participants with significant neurological disorders.
• ✕. Patients with chronic migraine with and w/o aura following the ICHD-3 criteria treated or not treated with medication